SEC For	rm 4																		
FORM 4 UN				O STA	ES S		Vashi	MMIS	SION		OMB	APPRO	VAL						
Section 16. Form 4 or Form 5 obligations may continue. See				ed ni	AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim	Estimated average burden		3235-0287 1 0.5	
1. Name and Address of Reporting Person* <u>ROWLAND LLOYD A</u>						2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [CTMX]									ck all applic Director Officer	able)	10% C ve title Other		Owner (specify
(Last)(First)(Middle)C/O CYTOMX THERAPEUTICS, INC.151 OYSTER POINT BLVD., STE. 400				_	3. Date of Earliest Transaction (Month/Day/Year) 02/02/2022									A below) below) General Counsel					
(Street) SOUTH SAN FRANCISCO			94080		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5	State)	(Zip)																
		Та	ble I - Nor	ו-Deri	vativ	ve S	ecuritie	s Ac	quired,	Dis		,			Owned				
1. Title of Security (Instr. 3)			Date		Transaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction C Code (Instr.		1 Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) or 4 and 5)	or 4 and 5) 5. Amount Securities Beneficial Owned Fo Reported		Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D) P		Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 02/02				2/20	2022		A		22,500	22,500 ⁽¹⁾ A		\$0.00	34,2	34,291 ⁽²⁾		D			
			Table II -								osed of, converti				Dwned				
1. Title of Derivative Security (Instr. 3) 2. Conversio Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	Code (Ins				6. Date Exercis Expiration Dat (Month/Day/Ye		e	of Secur Underly Derivati	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title		nber Shares					

Explanation of Responses:

\$4.13

Stock Option (Right to

Buy)

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

(3)

2. Includes 22,500 RSUs.

3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

<u>/s/ Lloyd Rowland</u>	<u>02/04/2022</u>
** Signature of Reporting Person	Date

135,000

\$0.00

135,000

D

Common

Stock

02/01/2032

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/02/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

135,000